Biomea Fusion Inc

NASDAQ BMEA

Download Data

Biomea Fusion Inc Operating Cash Flow Per Share for the quarter ending March 31, 2024: -0.89

Biomea Fusion Inc Operating Cash Flow Per Share is -0.89 for the quarter ending March 31, 2024, a -9.82% change year over year. Operating cash flow per share represents the amount of cash generated from a company's core operations per outstanding share. It is calculated by dividing the operating cash flow by the weighted average number of basic shares outstanding. This metric provides insights into the company's ability to generate cash flow from its day-to-day operations on a per-share basis. It is useful for evaluating the company's cash flow generation and comparing it with other companies on a per-share basis.
  • Biomea Fusion Inc Operating Cash Flow Per Share for the quarter ending March 31, 2023 was -0.81, a -136.84% change year over year.
  • Biomea Fusion Inc Operating Cash Flow Per Share for the quarter ending March 31, 2022 was -0.34, a -129.60% change year over year.
  • Biomea Fusion Inc Operating Cash Flow Per Share for the quarter ending March 31, 2021 was -0.15, a -535.02% change year over year.
  • Biomea Fusion Inc Operating Cash Flow Per Share for the quarter ending March 31, 2020 was -0.02.
NASDAQ: BMEA

Biomea Fusion Inc

CEO Mr. Thomas Andrew Butler
IPO Date April 16, 2021
Location United States
Headquarters 900 Middlefield Road, Redwood City, CA, United States, 94063
Employees 110
Sector Healthcare
Industry Biotechnology
Description

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Similar companies

EWTX

Edgewise Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email